M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
* Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A1
* The NXT007 clinical development programme aims to normalise...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search